MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology

- Technology provides more tools to fight difficult-to-treat diseases

- Company actively licensing its CRISPR-Cas9 technology for therapeutic and other uses

- Committed to ethical use of genome-editing technology

BURLINGTON, Mass., May 11, 2020 /PRNewswire/ -- MilliporeSigma, a leader in genome editing, today announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States. These allowances provide MilliporeSigma with the opportunity to support U.S. scientists and researchers in their work to advance gene therapy development programs. The company is in active discussions to license its foundational technology for therapeutic and other uses and is seeking collaboration partners for research and product development.

"This is important news for researchers, as CRISPR-based DNA tools are fundamental for many genome-editing applications and can be used to develop personalized therapies," said Udit Batra, CEO, MilliporeSigma. "As a leading innovator of CRISPR technology, we will license this technology to ensure that the full potential of this powerful tool is realized, responsibly and ethically, throughout the scientific community. We look forward to continuing our work with academic and industrial partners to bring the best of our collective innovations to fight the toughest diseases and improve human health."

These latest allowances cover MilliporeSigma's CRISPR-Cas9 cleavage and integration technology, which allows researchers to replace a disease-associated mutation with a beneficial or functional sequence, or delete such a mutation, commonly referred to as "knock in" and "knock out," critical methods for the creation of disease models and development of gene therapy.

These grants mark MilliporeSigma's 25^th and 26^th CRISPR patents worldwide and third and fourth in the U.S.  The company has CRISPR patents granted in Australia, Canada, China, Europe, Israel, Singapore and South Korea with related patent filings in Brazil, India and Japan. 

CRISPR technology is a core competency for MilliporeSigma, which has 16 years' experience with genome editing, spanning discovery to manufacturing. The company develops technologies in a range of genome-editing applications, including gene knockout, gene integration and CRISPR libraries for genetic screens. The company received its first U.S. patent in February 2019 for its proxy-CRISPR technology, which makes genome editing more efficient, flexible and specific.

MilliporeSigma considers that now is the time for the key CRISPR intellectual property stakeholders to come together to simplify technology access for companies conducting CRISPR-based research via patent pooling agreements. MilliporeSigma and The Broad Institute announced their collaboration agreement for CRISPR patent licensing in July 2019.

The company recognizes that genome editing has resulted in major advancements in biological research and medicine. At the same time, the growing potential of genome-editing technologies has led to scientific, legal and societal concerns. MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma's parent company, Merck KGaA, Darmstadt, Germany, has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing and has developed, defined and transparently published a clear operational Genome-Editing Technology Principle taking into account scientific and societal issues to inform promising therapeutic approaches for use in research applications.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.

SOURCE MilliporeSigma